Boehringer Ingelheim Launches First Licensed Treatment for Equine Insulin Dysregulation
Event summary
- Boehringer Ingelheim has launched the first licensed treatment for equine insulin dysregulation in Great Britain, targeting the leading cause of laminitis, which accounts for 25% of equine euthanasia cases in the UK.
- The treatment, developed over 14 years and backed by 19 studies, showed 0% laminitis development in treated ponies compared to 38% in untreated ponies in clinical trials.
- The oral treatment is available from veterinary surgeons across England, Scotland, and Wales starting September 2026.
- Insulin dysregulation affects 1 in 5 horses and ponies, often without obvious symptoms, making early detection and intervention critical.
The big picture
Boehringer Ingelheim's launch addresses a critical gap in equine health, where laminitis has been a leading cause of euthanasia with limited treatment options. The company's long-term investment in research positions it as a leader in addressing metabolic disorders in horses, a segment with high unmet medical need. This move aligns with broader industry trends toward specialized veterinary solutions and preventive care in animal health.
What we're watching
- Market Adoption
- The pace at which veterinarians and horse owners adopt this treatment will determine its commercial success and impact on equine welfare.
- Competitive Response
- Whether competitors will accelerate their own research or seek partnerships to develop alternative treatments for insulin dysregulation.
- Regulatory Expansion
- How quickly Boehringer Ingelheim can secure approvals in other markets beyond Great Britain, given the global prevalence of laminitis.